Eagle Pharmaceuticals (NASDAQ:EGRX) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research report released on Thursday. The firm issued a hold rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Price Performance

Shares of Eagle Pharmaceuticals stock opened at $0.95 on Thursday. The firm has a fifty day moving average price of $1.56 and a two-hundred day moving average price of $3.54. Eagle Pharmaceuticals has a fifty-two week low of $0.00 and a fifty-two week high of $9.00.

Institutional Trading of Eagle Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. grew its stake in shares of Eagle Pharmaceuticals by 0.4% in the 1st quarter. Vanguard Group Inc. now owns 640,754 shares of the specialty pharmaceutical company’s stock valued at $3,358,000 after purchasing an additional 2,630 shares during the period. Price T Rowe Associates Inc. MD acquired a new position in Eagle Pharmaceuticals in the first quarter valued at approximately $83,000. AIGH Capital Management LLC boosted its position in shares of Eagle Pharmaceuticals by 2.1% in the 2nd quarter. AIGH Capital Management LLC now owns 1,211,509 shares of the specialty pharmaceutical company’s stock worth $6,784,000 after purchasing an additional 25,000 shares during the last quarter. Vanguard Personalized Indexing Management LLC bought a new position in Eagle Pharmaceuticals during the second quarter worth about $76,000. Finally, XTX Topco Ltd acquired a new position in Eagle Pharmaceuticals during the second quarter valued at approximately $113,000. Institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.